Stem Cell Clinic

Update: Pacific Beach Elementary student’s ongoing battle with leukemia – A few months ago we introduced you to Ace Pringle the first-grader from…

By adminApril 15, 2020Stell Cell Research

Ace, first-grader at Pacific Beach Elementary, and his 3-year-old younger brother, Crue.

A few months ago, we introduced you to Ace Pringle, the first-grader from Pacific Beach Elementary who is battling Multiple Phenotype Acute Leukemia. Since then, Ace has been going through chemotherapy treatments and hoping for remission.

Recently, Aces doctors recommended that he get a bone marrow transplant.

With a bone marrow transplant, the Pringle family has a few different options to get a donation. They could sign up for the national registry, look into stem cell research, or find a donor. Just this Tuesday, the Pringle family found out that Aces 3-year-old brother, Crue, is a perfect match.

These next steps are going to be difficult, but the fact that Crues a match is huge, says Ace and Crues mother, Amber Pringle. As I look at this rambunctious 3-year-old, he has no idea whats to come for him.

While Ace has been going through chemotherapy, COVID-19 has swept across the world; but the Pringle family did not need to change their lifestyle as the city shut down. When COVID-19 came, we were already living on lockdown. We were already wearing masks to the store, says Amber. Its interesting that everything has caught up with us. Its so surreal.

Additionally, the virus has brought a silver lining to Aces battle with leukemia. Ace has been able to join his first-grade class at PB Elementary with distance learning, says Aces father, John Pringle.

Ace was homeschooled before the San Diego Unified School District stopped in-person classes due to COVID-19. Now, because of the shift to online learning, Ace has been able to rejoin his first-grade class on Zoom.

Its been nice for Ace to join his classmates, says John Pringle. He enjoys connecting with all his classmates all on one screen.

Never would I have imagined that all the kids would have this opportunity to do online learning, adds Amber Pringle.

Although the COVID-19 pandemic has allowed Ace to learn with the rest of his class, the virus has had an adverse effect on his parents. John and Amber, both small business owners who put their careers on hold to care for Ace, were just getting back to work before the virus reached the city.

Over the past few months, the Pringle family has received assistance from family and friends. Weve really had a lot of support and were extremely thankful to everyone who has helped out, says John Pringle.

Like the rest of the city and the nation, the Pringle family are staying home and keeping safe. Additionally, they are celebrating the fact that Crue will play a crucial role in helping his brother. For now, the family hopes that Ace will soon be in remission so that they can go ahead with the bone marrow transplant.

To help support Ace and his family, consider donating on their GoFundMe page at gofundme.com/f/ace-pringle-leukemia-fundraiser.

More here:
Update: Pacific Beach Elementary student's ongoing battle with leukemia - A few months ago we introduced you to Ace Pringle the first-grader from...

130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure – Lifesite

By adminApril 15, 2020Stell Cell Research

WASHINGTON, DC, April 15, 2020 (LifeSiteNews) More than 130 members of Congress urged President Donald Trump to maintain your current fetal tissue research policy and to redirect funds toward ethical, successful alternatives to combat COVID-19.

The pro-life representatives, including House Minority Leader Kevin McCarthy, thanked Trump in an April 14 letter for his decisive actions to protect human life and human dignity on every front, praising him for having brought great hope to our nation.

In the wake of the coronavirus outbreak in the United States, it has been argued by some that Trumps ban on aborted fetal tissue research by government scientists is thwarting efforts to find a remedy for the disease.

A senior scientist at a government biomedical research laboratory has been thwarted in his efforts to conduct experiments on possible treatments for the new coronavirus because of the Trump administrations restrictions on research with human fetal tissue, the Washington Post claimed in March.

Several of the leading COVID-19 vaccine developments, however, are using aborted fetal cells.

15 state Attorneys General had written to President Trump on March 26, stating that the use of aborted fetal tissue could help accelerate vaccine development to combat COVID-19, as well as study the impact to pregnant women and children.

We ask you to end your Fetal Tissue Ban to allow our top scientists the ability to solve this global health crisis, the Attorneys General concluded.

The more than 130 pro-life members of Congress responded to the allegations brought forward by proponents of aborted fetal tissue research, pointing out that they repeat false claims and narratives which for many years have touted the utility of aborted fetal tissue in research, including the claim that aborted fetal tissue has been used to create many vaccines.

The signers of the April 14 letter stressed that fetal tissue from ongoing abortions has never been used in production of a single vaccine. Instead, a few old cell lines from abortions performed in the 1960s and 1970s are used for a small handful of vaccines.

More importantly, most vaccines today use more efficient, modern cell lines and production techniques, the members of Congress explained.

Also, the few attempted transplants of aborted fetal tissue have resulted in making most patients worse, not better, they added.

The members of Congress showed that scientific progress and ethical behavior can go hand in hand.

The focus of the current appeals for taxpayer money to buy fetal tissue is the supposed necessity of using aborted baby body parts to construct humanized mice to test drugs. Yet, this antiquated technology has been surpassed by a plethora of modern, ethical techniques, as has been thoroughly described and cited in Congressional testimony.

Accusing the proponents of aborted fetal tissue research of exploiting the current situation for their own benefit, the pro-life representatives said that holding the line ethically gives us the ability to put resources toward better, more promising science that is already showing potential against COVID-19.

They specifically mentioned three projects.

First, they pointed to humanized mice that already exist, but are not based on aborted fetal tissue.

Then, they talked about [r]epurposing already-approved drugs also showing potential in treating coronavirus patients. At the end of March, the Food and Drug Administration (FDA) authorized experimental coronavirus treatments using anti-malaria drugs chloroquine and hydroxychloroquine.

Finally, they emphasized the great potential of adult stem cells, derived without destroying embryos and without abortion. One specific type of human adult stem cell, they said, has been shown to generate new lung tissue and heal damaged lungs, essential for repair of lungs damaged by respiratory viruses. Another was successful in improving the health of people suffering from pneumonia induced by the coronavirus.

Instrumental in drafting the letter was Congressman Lawrence Lamborn, representing Colorados 5th congressional district since 2007.

During this crisis, the last thing anyone should do is try and advance the lefts radical abortion agenda, Lamborn said. Life is precious at all stages and any claim to the contrary is unconscionable.

He is convinced that a cure for COVID-19 will be found, but using tissue from aborted babies to do so is unethical and wrong. Im thankful that President Trump has taken such a strong stand for life, and Im confident a solution can be found while also maintaining the sanctity of life.

Marjorie Dannenfelser, president of pro-life Susan B. Anthony List, praised the letter in a statement on Wednesday.

As millions of Americans work together to fight the coronavirus outbreak, the profit-driven abortion industry and their allies exploit fears surrounding the pandemic to promote an extreme abortion agenda, she noted.

Abortion supporters insist that unethical experiments involving aborted baby body parts are necessary to find a cure for the coronavirus, ignoring the wide variety of ethical options already available and under development, she continued.

We are greatly encouraged by the strong leadership of Sen. Wicker, Sen. Cindy Hyde-Smith, Rep. Lamborn, Rep. Latta, and all our pro-life allies in Congress who are fighting back against the abortion industrys attempts to exploit this national pandemic to advance their dangerous agenda.

See the original post here:
130+ congressmen urge Trump to keep ban on aborted fetal tissue research in race for COVID-19 cure - Lifesite

The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at…

By adminApril 15, 2020Stell Cell Research

New York, April 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User - Global Forecast to 2025" - https://www.reportlinker.com/p05881975/?utm_source=GNW

"The Neurostimulation & Neuromodulation Device is projected to witness the highest growth during the forecast period"

On the basis of Device, the Peripheral Nerve Repair Devices Market is studied across Biomaterial and Neurostimulation & Neuromodulation Device. The Biomaterial further studied across Nerve Conduit, Nerve Connector, Nerve Protector, and Nerve Wrap. The Neurostimulation & Neuromodulation Device further studied across External Neurostimulation Device and Internal Neurostimulation Device. The Biomaterial commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Neurostimulation & Neuromodulation Device is expected to grow at the fastest CAGR during the forecast period.

"The Nerve Grafting is projected to witness the highest growth during the forecast period"

On the basis of Application, the Peripheral Nerve Repair Devices Market is studied across Direct Nerve Repair/Neurorrhaphy, Nerve Grafting, Neurostimulation & Neuromodulation Surgery, and Stem Cell Therapy. The Direct Nerve Repair/Neurorrhaphy further studied across Epineural Repair, Group Fascicular Repair, and Perineural Repair. The Nerve Grafting further studied across Allograft, Autograft, and Xenograft. The Stem Cell Therapy commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Nerve Grafting is expected to grow at the fastest CAGR during the forecast period.

"The Ambulatory Surgery Center is projected to witness the highest growth during the forecast period"

On the basis of End User, the Peripheral Nerve Repair Devices Market is studied across Ambulatory Surgery Center and Hospital & Clinic. The Hospital & Clinic commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Ambulatory Surgery Center is expected to grow at the fastest CAGR during the forecast period.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

On the basis of Geography, the Peripheral Nerve Repair Devices Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Peripheral Nerve Repair Devices Market including Axogen Inc., Baxter International, Boston Scientific Incorporation, Cyberonics Inc., GlaxoSmithKline Pharmaceuticals Ltd., Integra LifeSciences Corporation, Medovent GmbH, Medtronic PLC, NeuroMetrix, Inc., Orthomed S.A.S., Polyganics B.V., Renerva, LLC,, St. Jude Medical, Stryker Corporation,, Synovis Micro Companies Alliance, Inc., and Toyobo Co., Ltd..

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peripheral Nerve Repair Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Peripheral Nerve Repair Devices Market?2. What are the inhibiting factors and their impact analysis shaping the Global Peripheral Nerve Repair Devices Market during the forecast period?3. What is the competitive position if vendors in the Global Peripheral Nerve Repair Devices Market?4. How Porters Five Forces define the Global Peripheral Nerve Repair Devices Market landscape?5. What are the technology trends and regulatory frameworks in the Global Peripheral Nerve Repair Devices Market?6. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peripheral Nerve Repair Devices Market?7. What is the competitive strategic window for opportunities in the Global Peripheral Nerve Repair Devices Market?8. What arRead the full report: https://www.reportlinker.com/p05881975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at...

Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 – Germany English News

By adminApril 15, 2020Stell Cell Research

Stem Cell Assay Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Stem Cell Assay market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Stem Cell Assay is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Stem Cell Assay market was valued at USD _ million/billion.

This research report based on Stem Cell Assay market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Stem Cell Assay market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Stem Cell Assay industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13462

Stem Cell Assay Market Overview:

The Research projects that the Stem Cell Assay market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Stem Cell Assay Market:

The major players in the global stem cell assay market include GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix Inc., Stemcell Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13462

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13462

The Questions Answered by Stem Cell Assay Market Report:

And Many More.

Go here to read the rest:
Stem Cell Assay Market : Information, Figures and Analytical Insights 2019-2025 - Germany English News

Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects – Science In Me

By adminApril 15, 2020Stell Cell Research

The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry.

The global Mesenchymal Stem Cells Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Mesenchymal Stem Cells Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Apply Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/720

Geographical segmentation of Mesenchymal Stem Cells Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Mesenchymal Stem Cells Market: Competitive Landscape

Leading players operating in the global Mesenchymal Stem Cells Market include: Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

Scope of the Report

The key features of the Mesenchymal Stem Cells Market report 2019-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Mesenchymal Stem Cells Market. The structure of Mesenchymal Stem Cells Market by identifying its various segments and sub-segments to help understanding the report.

Mesenchymal Stem Cells Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Mesenchymal Stem Cells Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Mesenchymal Stem Cells Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/720

Important Mesenchymal Stem Cells Market Data Available In This Report:

Buy This Research Study Report @ https://www.coherentmarketinsights.com/insight/buy-now/720

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

For More Related Reports: http://bit.ly/Rajkumar123

See the article here:
Mesenchymal Stem Cells Market 2020-2026: Analysed by Business Growth, Development Factors, Applications, and Future Prospects - Science In Me

Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography – Salamanca Press

By adminApril 15, 2020Stem Cell Medicine

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Continued here:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Salamanca Press

UCSD scientists find possibilities for injured brain cells to be repaired – fox5sandiego.com

By adminApril 15, 2020Stem Cell Medicine

SAN DIEGO (CNS) Injured adult brain cells revert to an embryonic state and become capable of re-growing new connections, which under the right conditions can help restore lost brain function, according to findings published Wednesday by researchers at UC San Diego School of Medicine.

The findings, published in the academic journal Nature, were part of a collaborative study between UC San Diego, UCLA and the University of Tennessee.

Repairing damage to the brain and spinal cord, until relatively recently, seemed an impossible task. The new study lays out a transcriptional roadmap of regeneration in the adult brain.

Using the incredible tools of modern neuroscience, molecular genetics, virology and computational power, we were able for the first time to identify how the entire set of genes in an adult brain cell resets itself in order to regenerate, said senior author Dr. Mark Tuszynski, professor of neuroscience and director of the Translational Neuroscience Institute at UC San Diego School of Medicine. This gives us fundamental insight into how, at a transcriptional level, regeneration happens.

Using a mouse model, Tuszynski and colleagues discovered that after injury, mature neurons in adult brains revert back to an embryonic state.

Who would have thought, Tuszynski said. Only 20 years ago, we were thinking of the adult brain as static, terminally differentiated, fully established and immutable.

To provide an encouraging environment for regrowth, Tuszynski and colleagues investigated how damaged neurons respond after a spinal cord injury. In recent years, researchers have significantly advanced the possibility of using stem cells to spur spinal cord injury repairs and restore lost function, essentially by inducing neurons to extend nerve fibers through and across an injury site, reconnecting severed nerves.

The latest study produced a second surprise: In promoting neuronal growth and repair, one of the essential genetic pathways involves the gene Huntingtin, which, when mutated, causes Huntington*s disease, a devastating disorder characterized by the progressive breakdown of nerve cells in the brain.

While a lot of work has been done on trying to understand why Huntingtin mutations cause disease, far less is understood about the normal role of Huntingtin, Tuszynski said. Our work shows that Huntingtin is essential for promoting repair of brain neurons. Thus, mutations in this gene would be predicted to result in a loss of the adult neuron to repair itself. This, in turn, might result in the slow neuronal degeneration that results in Huntingtons disease.

Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production – ENGINEERING.com

By adminApril 15, 2020Induced Pluripotent Stem Cells

Parker Hannifin has sponsored this post.

Cell therapies promise treatments for serious illnesses, but require automation and manufacturing expertise to scale up production for research and products. (Image courtesy of Parker Hannifin.)

Cellular therapies and bio-fabrication are two of the most revolutionary treatments for serious illnesses to be developed in the early 21st century, offering the hope of cures where once only symptomatic treatments were available. The 2006 discovery of Induced Pluripotent Stem Cells (iPSCs) formed a catalyst for research and development into these new therapeutic approaches. Stem cell therapies offer promising avenues for the treatment of devastating illnesses such as diabetes, cancer, heart disease and even neurological diseases.

Tailored cell therapies using iPSCs are considered to be the new Third Pillar of the drug and treatment industry, standing alongside small molecules and biologics as tools for treatment. However, the widespread research and treatment using cell therapies requires mass-produced iPSCs to be available in quantitywhich means advanced manufacturing techniques.

Cells are tiny living, complex organisms; they must be handled with precision and accuracy. Automated handling equipment needs a heightened level of dexterity and control. (Image courtesy of Parker Hannifin.)

Scaling up the production of iPSCs requires investmentsome of which is already in place with two deals: $70 million to the New Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to advance U.S. leadership in the biopharmaceutical industry, and an 87-member coalition funded by the Defense Department called ARMI-BioFab USA, which aims to develop the next-generation techniques needed to repair and replace cells, tissues and organs for wounded military service veterans.

The key to success in the scale-up of production is advanced automation, which will improve the manufacturing process used to fabricate cell colonies.

Currently, most research and cell fabrication involves a significant amount of manual work and decision-making, which can be error-prone and represents a bottleneck in attempts to scale these fabrication processes.

One way to improve the manufacturing processes related to cell therapies is by partnering with experienced automation and manufacturing industry leaders, who can share their expertise. An example of this is the partnership between Parker Hannifin and CellX Technologies. Together, these companies have developed a platform to help researchers and clinicians quantify key morphological stem cells, automate the handling process and perform cell maintenance.

Current cell therapy research is hampered by difficulties with a lack of large field-of-view and high-resolution optics when imaging live cell cultures. This makes it difficult to monitor and quantify changes to the cells. Available devices and equipment for sampling, transfer or deletion of specific cells or colonies also lack the rigorous accuracy that manufacturing-scale production would require. Instead, visual assessment and manual transfer by lab technicians is the usual methodsacrificing speed and production volume.

An automated, image-based system would enable accurate quantitative metrics of biological performance and will be applicable at a cell-by-cell or a colony-by-colony basis, among other benefits.

Automated cell-handling equipment needs to be precise and finely calibrated in order to handle delicate cells with the necessary dexterity and control. Three primary handling techniques are used for this very difficult automation task:

Combining capabilities for these three functions into a single platform will enable multiple benefits, including improved reproducibility and quality of cells for research and products, reduce variability and costs from manual processes, improved lot traceability and documentation, and define quantitative process quality attributes and metrics.

Parker Hannifins expertise in manufacturability, digital pathology and additive manufacturing lends itself directly to the development of the CellX platform. CellX enables automation of the scanning and identification processes, and pairs this with cell selection and precision placement.

The CellX Device, developed by Parker Hannifin and CellX Technologies, combines large field-of-view imaging with precision instrumentation, fluidics, and documentation and control capabilities. (Image courtesy of Parker Hannifin.)

CellX also needed customization of standard products. Parker Hannifin has decades of experience in close tolerance special purpose fluidics and actuator technology, and developed enabling technology for the CellX central core, which consists of a high-quality automated inverted microscope and CCD camera with brightfield and fluorescent imaging capabilities.

Some of the specialized equipment that Parker Hannifin helped develop for CellX includes a load and removal station for disposable cell-picking tips, and environmentally controlled workspace to maintain sterility and oxygen levels, and an integrated sensor to accurately locate each new tip.

The combined precision and imaging capabilities of the CellX platform enable rapid data collection and high repeatability, which means researchers can rely on accurate data, healthy cell colonies and quantitative, reproducible standards for cell therapy development. Parker Hannifin has a proven history of developing new tools and instruments for manufacturing processes with their partner OEMsand in the case of CellX, accelerating the development of the future of cell therapies.

To learn more about Parker Hannifins development of the CellX platform, including use cases and details on the full complement of customized equipment and enabling features, download the full whitepaper from Parker Hannifin.

See more here:
Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com

Stem cell treatment works for many, but insurance doesn’t cover it – msnNOW

By adminApril 15, 2020Stem Cell Treatment

Click to expand

UP NEXT

Still waiting for stem cell treatments to come to a doctor's officenear you?

It seems like a decade or two since we were introduced to stem cell research and treatments,and told that, through them,we might beat the degradation of a dreaded disease, recover from an injury or a degenerated joint, and that all these could be things of the past.

All we'd need to do was get an injection of our own stem cells and like magic we'd be up and running again almost like new.Let the body heal itself.Sounds like a dream.

Well in some circles this is more than a dream: Its happening.

Recently I spoke with Mark Berman, a doctor in Beverly Hills, about his Cell Surgical Network: Amore than decade-old business that's busy advancing medical research by using a network of doctor's following specific stem cell protocols.He networks with over 100 doctors in the U.S. and abroad who are enthusiastic about the potential of stem cells and want to see stem cell treatments become a normal part of health care.

To have a betteridea of the protocol, I visited the office of long-time Redding physician Robert Ghelfi, who is in Berman's network.Ghelfiis the medical director of the Northern California Stem Cell Treatment Center that affiliates with several Redding physicians.

He explained the stem cell extraction method: Takea little fat from the patient and spinit to separate the stem cells. Onceseparated, Ghelfiprepares the patients own stem cells forinjection into the injured, damaged or degenerating site on the patient's body.It seems like a surprisingly simple and straightforward procedure. It typically takes one injection,Ghelfisaid, and the visit lasts about an hour.

UP NEXT

Stem cells are attracted to injured, damaged or ill-performing tissue, Berman and Ghelfi explained.Once injected into the region, they begin to heal and regenerate tissue.

How effective is it?

It depends on the area of the body and the problem.

Both Berman and Ghelfi mentioned the 83% success rate they've had with injecting over 6,000 degenerated knees. This treatment is popular with people who opted not to have a knee replacement surgery.

A complication with younger people getting knee replacements is the need for another replacement years later, since the first can wear out. With stem cell therapy, this problem can be avoided, Ghelfi said.

Research shows success with other conditions as well.

For his part, Ghelfi is impressed by the research,and his own clinical experience,using stem cells for the treatment of chronic obstructive pulmonary disease (COPD).

Under the heading of COPDfalls chronic bronchitis and emphysema. Since chronic bronchitis usually progresses to emphysema, Ghelfis goalis to try to stabilize pulmonary function.

"This is a huge improvement for COPD since the rate of decline annually is fourpercent," he said. And since pulmonary function is easily measurable, it works nicely forresearch data.

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

By adminApril 15, 2020Stem Cell Treatment

Orgenesis to Acquire Tamir Biotechnology's Assets for $19 Million

Orgenesis Inc. (ORGS) reported that it has signed a deal with Tamir Biotechnology Inc., under which the former will acquire the assets of the latter, including its broad spectrum antiviral platform ranpirnase. The deal is cash- and stock-based and is expected to be worth nearly $19 million. Orgenesis plans to merge ranpirnase with its co-developed Bioxome technology for improving payload delivery direct to the cells.

Combined with ranpirnase, Bioxomes have showed the ability to fuse with cell membranes and delivering an intracellular cargo, mimicking the working of natural exosomes. Bioxomes, when loaded with predesignated genetic material, proteins, signaling molecules and drugs, copy the natural membrane fusion capacities of exosomes. This feature may help in providing more efficient antiviral results.

TamirBio is a clinical-stage company focusing on developing treatments for viruses and other pathological conditions. Its lead asset, ranpirnase, is a ribonuclease and belongs to a superfamily of enzymes which may catalyze the degradation of RNA. It may also mediate in different essential biological activities, such as the regulation of cell proliferation, differentiation, maturation and death. According to Orgenesis, this feature makes it suitable for treating viral and autoimmune diseases which require therapies with anti-proliferative and apoptotic properties.

TamirBio has used these properties for developing topical ranpirnase for treating human papillomavirus, a leading cause of genital warts. The drug candidate has been evaluated in Phase I/II clinical trial for genital warts, and the results demonstrated clear clinical effects. The company plans to hold additional clinical trials. Orgenesis CEO Vered Caplan said, In independent third-party testing, ranpirnase has shown anti-viral activity in multiple viruses. Additionally, over 1,000 patients have been dosed with ranpirnase in previous cancer/mesothelioma clinical trials. Ranpirnase demonstrated a strong safety and tolerability profile that should help accelerate the approval pathway. TamirBio claims that the drug candidate has shown preclinical antiviral activity in such viral diseases as HPV, HIV, Ebola, and SARS.

Orgenesis also provided updates about its operating activities and reported that its research & development labs are still working. In February, the company sold its subsidiary Masthercell Global Inc. to Catalent Pharma Solutions for nearly $127 million. Masthercell was a contract development manufacturing organization. Orgenesiss CGT Biotech Platform mainly consists of three core components, which are POCare Therapeutics, POCare Technologies, and POCare Network. The CGT Biotech Platform aims to decentralize the CGT supply chain.

The company also recently entered into a new joint venture with Revatis. The partnership will work towards providing autologous cell therapies with exosomes and other cellular products obtained from muscle-derived mesenchymal stem cells. The task of making the stem cells will be entrusted to Revatis, which will use its minimally invasive muscle biopsy technique and isolator technology for this purpose. Orgenesis will be responsible for providing clinical and regulatory expertise and access to its point-of-care (PoC) technology. This POCare platform provides access to a global network of hospitals and research institutes which may be used for carrying out clinical trials for developing life-saving therapies.

Teladoc Health Inc. (TDOC) stock showed solid gains as the ongoing pandemic has put a spotlight on telemedicines. The company has seen a surge in the download of its app BetterHelp, which has a virtual behavioral health offering. According to a research note released by Bank of America Global Research, the app had the download volume of nearly 1000 per day in March, which has now surged to over 1800 per day.

While telemedicine has been around for quite some time, the current scenario has led to mass acceptance of this virtual practice. Due to strict restrictions on movement and the unprecedented burden on healthcare services, telemedicine has proved to be a boon for people with non-critical ailments. Under the 1135 waiver authority and the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, the scope of telehealth facilities has been widened to include coverage for office, hospital and other visits equipped with telehealth facilities in the United States and at patients residences.

The Teladoc platform was recently deployed by Tower Health for offering virtual health care for patients suffering from different ailments. Each visit was provided at $45 and is available 24 hours a day, 7 days a week. Apart from COVID 19, some of the other prominent health issues addressed by the platform are flu symptoms, respiratory infection and rashes. Dr. Lewis Levy, chief medical officer of Teladoc, said, There is no doubt that we are seeing positive momentum and that awareness has increased. Telemedicine is now a household term.

It is estimated that the global telehealth market is expected to register 16.9 percent CAGR during the 2020-2025 forecast period. It will likely be worth $55.6 billion by 2025, up from current valuation of $25.4 billion in 2020. The low-risk and high-efficiency nature of these services are making them very popular now.

Pluristem Therapeutics Inc. (PSTI) reported that it has treated its first patient suffering from complications arising from the novel coronavirus. The patient was treated under the FDA Single Patient Expanded Access Program, and PLX cell therapy was used for this purpose. The company is now looking to initiate a multinational clinical trial at the earliest possible.

Pluristem further said that the patient was in critical condition with respiratory failure due to acute respiratory distress syndrome. The patient was in an intensive care unit with mechanical ventilation for three weeks. Single Patient Expanded Access Program is also known as a compassionate use program and is a part of the US Coronavirus Treatment Acceleration Program. The program is mainly aimed at accelerating the development of new therapies for dealing with this disease.

Pluristem focuses on using PLX cell treatment regimen. These cells are available off the shelf and may be manufactured in bulk quantities. Pluristem CEO and President Yaky Yanay said, We are receiving many inquiries and requests for treatment from healthcare providers and families worldwide. In parallel with our planned clinical trial, we expect to continue treating patients under compassionate use through the appropriate regulatory clearances in the United States and Israel, as well as expanding treatment under compassionate use in other countries. PLX cells are allogeneic mesenchymal-like cells and demonstrate immunomodulatory properties.

Pluristem Therapeutics is mainly invested in developing regenerative medicines and placenta-based cell therapy products. The company has solid development pipeline and has several products in late-stage clinical trials. PLX cell drug candidates are expected to work by releasing different therapeutic proteins in response to radiation damage, inflammation, muscle trauma and ischemia. Pluristem also owns and manages a GMP certified research and manufacturing facility.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See the original post:
Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha